Allogeneic bone marrow transplantation for low-grade lymphoma.
Allogeneic bone marrow transplantation for low-grade lymphoma.
复制标题
同种异体骨髓移植治疗低度恶性淋巴瘤。
DOI：
10.1182/blood.v92.5.1832.417a04_1832_1836
复制
发表时间：
1998
期刊：
影响因子：
20.3
通讯作者：
M. Horowitz
中科院分区：
文献类型：
--
作者：
K. Besien;K. Sobocinski;P. Rowlings;Sandra C. Murphy;James O. Armitage;Michael R. Bishop;O. Chaekal;R. P. Gale;John P. Klein;H. Lazarus;P. McCarthy;J. Raemaekers;Josy Reiffers;Phillips Gl;A. Schattenberg;L. Verdonck;J. Vose;M. Horowitz
晚期低度恶性淋巴瘤通常无法用常规剂量化疗治愈。目前还不确定是否有可能通过大剂量治疗和人类白细胞抗原（HLA）相同的同胞骨髓移植治愈。我们试图确定HLA相合同胞骨髓移植治疗晚期低度恶性淋巴瘤的结果，在50个参加国际骨髓移植登记中心（IBMTR）的113例患者中进行了一项观察性研究。患者年龄中位数为38岁（范围：15 - 61岁）。80%在移植时患有IV期疾病。既往化疗方案的中位数量为2（范围，0 - 5）。38%患有难治性疾病，29%的Karnofsky表现评分（KPS）低于80%。所有患者均接受来自HLA相合同胞供者的异基因骨髓移植。预处理方案包括82%的患者接受全身照射（TBI）; 74%的患者使用环孢素预防移植物抗宿主病。确定生存率、无病生存率、复发率、治疗相关死亡率和死亡原因。3年复发率、生存率和无病生存率的概率分别为16%（95%置信区间[CI]，9%-27%）、49%（95% CI，39%-60%）和49%（95% CI，39%-59%）。移植前KPS>/= 90%、化疗敏感性疾病、使用含TBI的预处理方案和年龄小于40岁的患者生存率较高。我们的结论是，高剂量治疗后，从HLA相同的同胞移植导致一些晚期低度恶性淋巴瘤患者的生存期延长。大多数死亡率与治疗有关，复发率罕见。
Advanced low-grade lymphomas are usually incurable with conventional-dose chemotherapy. It is uncertain whether cures are possible with high-dose therapy and bone marrow transplant from a human leukocyte antigen (HLA)-identical sibling. We sought to determine the outcome of HLA-identical sibling bone marrow transplants in advanced low-grade lymphoma in an observational study of 113 patients conducted at 50 centers participating in the International Bone Marrow Transplant Registry (IBMTR). The median patient age was 38 years (range, 15 to 61). Eighty percent had stage IV disease at the time of transplantation. The median number of prior chemotherapy regimens was two (range, 0 to 5). Thirty-eight percent had refractory disease and 29% a Karnofsky performance score (KPS) less than 80%. All patients underwent allogeneic bone marrow transplantation from a HLA-identical sibling donor. The conditioning regimen included total-body irradiation (TBI) in 82% of patients; cyclosporine was used for graft-versus-host disease prophylaxis in 74%. Survival, disease-free survival, recurrence rate, treatment-related mortality, and causes of death were determined. Three-year probabilities of recurrence, survival, and disease-free survival were 16% (95% confidence interval [CI], 9% to 27%), 49% (95% CI, 39% to 60%), and 49% (95% CI, 39% to 59%), respectively. Higher survival was associated with pretransplant KPS >/=90%, chemotherapy-sensitive disease, use of a TBI-containing conditioning regimen, and age less than 40 years. We conclude that high-dose therapy followed by transplantation from a HLA-identical sibling leads to prolonged survival in some patients with advanced low-grade lymphoma. Most mortality is treatment-related, and recurrences are rare.
与同种异体骨髓移植相关的移植物抗淋巴瘤效应的证据。
影响因子：
20.3
作者：
Jones,RJ;Ambinder,RF;Piantadosi,S;Santos,GW
通讯作者：
Santos,GW
自体骨髓移植后的骨髓增生异常综合征：治愈性癌症治疗的另一个晚期并发症。
影响因子：
20.3
作者：
Miller,JS;Arthur,DC;Litz,CE;Neglia,JP;Miller,WJ;Weisdorf,DJ
通讯作者：
Weisdorf,DJ
对 69 名有低度 B 细胞非霍奇金淋巴瘤病史的患者进行自体骨髓移植。
影响因子：
20.3
作者：
Freedman,AS;Ritz,J;Neuberg,D;Anderson,KC;Rabinowe,SN;Mauch,P;Takvorian,T;Soiffer,R;Blake,K;Yeap,B
通讯作者：
Yeap,B